Max Healthcare Institute Ltd. issues fresh guidance

The roadmap implies 1,101 additional beds over FY27–FY28, with estimated capex outflow of Rs 4,365 Crores—Rs 2,340 Crores in FY27 plus Rs 2,025 Crores in FY28. The Aug 2026 figure of 6,183 beds represents the existing/current capacity base, not a further 6,183-bed addition. ^[1]

† Derived from Rs 848 Crores CWIP and Rs 1,122 Crores cash; CWIP is an asset already under construction, not immediately available liquidity.

Interpretation: the planned two-year outflow is approximately 5.15x the reported CWIP and 3.89x the reported cash balance, on the network balance-sheet basis. Thus, the expansion is not fully pre-funded by the existing balance-sheet cash position. It will need to be supported by operating cash generation, project phasing, asset-light or partner-funded structures, and potentially incremental borrowing. Management reported Rs 397 Crores of Q1 FY27 cash generation from operations and net debt of Rs 2,384 Crores as of June 30, 2026, indicating some funding capacity but also an existing leverage base. ^[3]

Period caveat: the balance-sheet table cited in the Q1 FY27 presentation is labelled March 2026, not June 2026; therefore, Rs 848 Crores CWIP and Rs 1,122 Crores cash are the latest network figures disclosed in that table, rather than a confirmed Q1 FY27 quarter-end balance-sheet snapshot. The statutory consolidated Q4 FY26 figures were lower at Rs 592.24 Crores CWIP and Rs 665.80 Crores cash. ^{[4] [5]}

The presentation does not separately report a line item called “high-end clinical services.” A reasonable high-acuity proxy is the combined share of oncology, cardiac, neuro, renal, and liver/biliary services: 55.9% of gross inpatient revenue, derived from the specialty mix. Against Q1 FY27 gross inpatient revenue of Rs 2,346 Crores, this implies approximately Rs 1,311 Crores of revenue, but this is an analyst-derived proxy rather than a separately reported company metric. ^[6]

†Derived as 22.2% + 10.1% + 9.8% + 9.9% + 3.9% of gross inpatient revenue; the presentation itself does not label this subtotal “high-end clinical services.”

Implication: the ARPOB thesis is principally a mix-and-yield strategy: a substantial share of inpatient revenue already comes from complex specialties, while the 75% occupancy level indicates further volume/utilization headroom. However, without a reported ALOS figure, the quarter cannot be assessed on whether higher ARPOB was accompanied by shorter or longer patient stays.

The roadmap has moved beyond early-stage targeting for several assets: Kalinga Hospital, Bhubaneswar has already been acquired; the Pune/Yerawada transaction has a signed SPA and was subsequently reported as completed; while Vaishali and Shaheed Path, Lucknow have board-approved investments. Mohali, Thane, Dehradun and Pitampura are covered by executed asset-light/O&M arrangements rather than outright acquisitions.

Debt-to-equity sensitivity

The company has not disclosed a project-by-project funding mix or a pro forma FY27 debt-to-equity ratio. The following is therefore a mechanical debt-funded scenario, not management guidance.

• At March 2026, reported gross debt was Rs 2,924 Crores and shareholders’ equity was Rs 12,088 Crores, implying gross debt-to-equity of 0.24x (derived) ^[2].
• The three disclosed amounts with clear values—Kalinga Rs 298 Crores, Lucknow Rs 1,400 Crores and Vaishali Rs 425 Crores—sum to approximately Rs 2,123 Crores (derived) ^{[9] [10] [12]}.
• If that entire amount were incremental debt-funded against the March balance sheet, gross debt-to-equity would rise to approximately 0.42x, from 0.24x—an increase of roughly 0.18x, or 18.00 percentage points (derived).

A broader presentation-level sensitivity uses the Rs 2,340 Crores of estimated FY27 expansion outflow. If the full amount were debt-funded, gross debt-to-equity would be approximately 0.44x, an increase of 0.19x from the March 2026 base (derived) ^{[1] [2]}.

Because Kalinga was already completed and current net debt was Rs 2,384 Crores at 30 June 2026, the remaining disclosed board-approved cash commitments—Lucknow and Vaishali, Rs 1,825 Crores—would imply net debt-to-equity of approximately 0.35x versus a 0.20x current proxy, using March equity as the latest disclosed denominator (derived) ^{[3] [2]}. The actual outcome should be lower if internal accruals, operating cash flow or equity funding offsets the borrowing; it could be higher once the undisclosed Pune consideration and costs of the executed asset-light agreements are included.